Inventor · disambiguated record
Alan Hruza
Also filed as: HRUZA ALAN · HRUZA ALAN W · HRUZA ALAN WILLIAM
25 granted patents·2 pending applications·234 citations·filing 1993–2021
94Inventor score
Top patents by PatentIndex Score
27 records- 0193US7807672B2Compounds that are ERK inhibitorsSCHERING CORP·Filed 2007·Granted Oct 5, 2010·16 cites·23 claims
- 0288US5602232AMethod for producing metal-interferon-α crystalsSCHERING CORP·Filed 1994·Granted Feb 11, 1997·70 cites·17 claims
- 0388US5441734AMetal-interferon-alpha crystalsSCHERING CORP·Filed 1993·Granted Aug 15, 1995·71 cites·23 claims
- 0487US7968683B1Factor IXa crystals, related complexes and methodsSCHERING CORP·Filed 2009·Granted Jun 28, 2011·7 cites·16 claims
- 0586US8546404B2Compounds that are ERK inhibitorsCOOPER ALAN B·Filed 2007·Granted Oct 1, 2013·9 cites·76 claims
- 0679US10123995B2Factor XIa inhibitorsMERCK SHARP & DOHME·Filed 2016·Granted Nov 13, 2018·2 cites·14 claims
- 0776US10011585B2Factor XIa inhibitorsMERCK SHARP & DOHME·Filed 2015·Granted Jul 3, 2018·2 cites·12 claims
- 0876US6004549ACrystalline protein controlled release compositionsSCHERING CORP·Filed 1994·Granted Dec 21, 1999·51 cites·23 claims
- 0974US10081617B2Factor XIa inhibitorsMERCK SHARP & DOHME·Filed 2016·Granted Sep 25, 2018·2 cites·11 claims
- 1073US10414774B2Compound useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolc diseaseMERCK SHARP & DOHME·Filed 2017·Granted Sep 17, 2019·1 cites·18 claims
- 1171US8710188B2Factor IXa crystals, related complexes and methodsBEYER BRIAN M·Filed 2011·Granted Apr 29, 2014·1 cites·5 claims
- 1265US9676723B2Factor XIa inhibitorsMERCK SHARP & DOHME·Filed 2015·Granted Jun 13, 2017·1 cites·16 claims
- 1365US9663527B2Factor XIa inhibitorsMERCK SHARP & DOHME·Filed 2015·Granted May 30, 2017·1 cites·14 claims
- 1462US8679472B1Crystal of human interferon alpha 2B in complex with zincREICHERT PAUL·Filed 2007·Granted Mar 25, 2014·0 cites·12 claims
- 1561US7824491B2Method for crystallizing aurora 2 kinase catalytic domain polypeptideSCHERING CORP·Filed 2008·Granted Nov 2, 2010·0 cites·5 claims
- 1661US7722718B2Methods for crystallizing ERK2 polypeptidesSCHERING CORP·Filed 2007·Granted May 25, 2010·0 cites·5 claims
- 1761US7422885B1Crystalline form of the catalytic domain of Aurora 2 kinase and methods of use thereofSCHERING CORP·Filed 2004·Granted Sep 9, 2008·0 cites·3 claims
- 1856US7312061B2ERK2 crystalsSCHERING CORP·Filed 2005·Granted Dec 25, 2007·0 cites·12 claims
- 1955US12492187B2Factor XI activation inhibitorsMERCK SHARP & DOHME LLC·Filed 2021·Granted Dec 9, 2025·0 cites·11 claims
- 2055US12428397B2Factor XI activation inhibitorsMERCK SHARP & DOHME LLC·Filed 2021·Granted Sep 30, 2025·0 cites·13 claims
- 2148US7511063B2High affinity quinoline-based kinase ligandsSCHERING CORP·Filed 2006·Granted Mar 31, 2009·0 cites·51 claims
- 2247US2010190231A1Methods for crystallizing erk2 polypeptidesSCHERING CORP·Filed 2010·Application pending·0 cites
- 2341US2007191604A1Novel compounds that are ERK inhibitorsCOOPER ALAN·Filed 2006·Application pending·0 cites
- 2440US10189819B2Factor IXa inhibitorsMERCK SHARP & DOHME·Filed 2015·Granted Jan 29, 2019·0 cites·14 claims
- 2540US9944643B2Factor XIa inhibitorsMERCK SHARP & DOHME·Filed 2015·Granted Apr 17, 2018·0 cites·10 claims
- 2639US9975874B2Factor XIa inhibitorsMERCK SHARP & DOHME·Filed 2015·Granted May 22, 2018·0 cites·16 claims
- 2738US10414775B2Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic diseaseMERCK SHARP & DOHME·Filed 2017·Granted Sep 17, 2019·0 cites·18 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →